Straits Times Index
3,435.00 +19.49 (+0.57%) Nikkei
40,741.58 +160.82 (+0.40%) Hang Seng
18,008.61 +30.04 (+0.17%) FTSE 100
8,171.12 +49.92 (+0.61%) Bitcoin USD
59,013.42 -1,873.13 (-3.08%) CMC Crypto 200
1,236.82 -98.09 (-7.35%)
Teva Pharmaceutical Industries Limited (TEVA.TA)
| Previous close | 6,131.00 |
| Open | 6,200.00 |
| Bid | 6,300.00 x 200 |
| Ask | 6,302.00 x 34100 |
| Day's range | 6,181.00 - 6,302.00 |
| 52-week range | 2,786.00 - 6,494.00 |
| Volume | |
| Avg. volume | 1,457,485 |
| Market cap | 71.379B |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Nov 2017 |
| 1y target est | N/A |
- Business Wire
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
TEL AVIV, Israel, July 02, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
- Business Wire
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
TEL AVIV, Israel, June 28, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY® (fremanezumab) that may challenge the rationale for treatment pauses with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) mandated or recommended by some reimbursement authorities after one year of continuous use.
- Business Wire
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
TEL AVIV, Israel, June 25, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company's taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029.
